HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $40 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a $40 price target.
July 11, 2023 | 10:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Viridian Therapeutics and maintained a $40 price target.
The reiteration of a 'Buy' rating and maintenance of a $40 price target by HC Wainwright & Co. indicates a positive outlook for Viridian Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100